Malignant obstructive jaundice
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. 18-80 years old; 2. The unresectability of potential malignant tumors (the obstructive site is located at the distal hilum of the liver > 2cm) was determined through MDT consultation. 3. Initial ERCP failure (intestinal stenosis/After digestive tract reconstruction/intubation failure); 4. Histopathological diagnosis of malignant tumors or a 6-month combined follow-up with imaging for the diagnosis of malignant tumors; 5. Jaundice or abnormal liver function; 6 EUS and/or CT and/or MRI revealed intrahepatic bile duct dilation (left side > 3mm); 7. Agree to participate in the study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. In patients with coagulation dysfunction (INR>1.3), the peripheral blood microplate count was significantly reduced to <50 × 10^9/L 2. Pregnant women 3. High biliary obstruction 4. Refuse to participate in the study and do not sign the informed consent form;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of stent dysfunction within 6 months;Stent patency time (median); | — |
Secondary
| Measure | Time frame |
|---|---|
| Surgical time;Technical success rate and clinical success rate;Postoperative adverse events;Surgical expenses;Hospitalization expenses; | — |
Countries
China
Contacts
The Second Hospital of Hebei Medical University